Second-Line Treatments — When Steroids Are Not Enough

This page explains what happens when steroids alone haven't been enough to control a severe immune reaction from immunotherapy — it is not a guide to managing a worsening reaction at home. If you or a family member currently has severe or worsening symptoms while on steroids, get emergency help first; the explanation below can wait until you're safe.

If a severe immune-related side effect from immunotherapy doesn't improve enough on steroids within the expected window, your specialist adds a second-line treatment rather than simply continuing steroids for longer or raising the dose indefinitely. Depending on the organ affected, this is usually an additional immune-suppressing medicine, or a targeted biologic medicine that blocks a specific inflammation pathway, given alongside continued steroid treatment and close monitoring. NCCN and ASCO guidance sets out this step-up approach across most organ systems affected by severe irAEs.

This page describes these options at a class level rather than naming specific medicines, because the right choice depends on which organ is involved, how severe the reaction is, and your individual case — a decision made by your treating specialist, not something to research and request yourself.

Your oncology team, together with the relevant organ specialist — a gastroenterologist for colitis, a pulmonologist for pneumonitis, a cardiologist for myocarditis, and so on — reviews how much your symptoms and blood tests have improved after a defined period on steroids, typically ranging from a few days to about a week depending on the reaction. If improvement is inadequate, or symptoms worsen despite steroids, second-line treatment is added promptly rather than waiting longer, because delay for a severe reaction carries its own risk.

Reaction severity grade and the specific organ affected both shape which second-line option your specialist recommends — there is no single next step that applies to every patient or every organ.

Not always. Whether immunotherapy can resume depends on the organ affected, how severe the reaction was, and how completely it settles with treatment. Some patients who needed second-line treatment for a moderate reaction later resume immunotherapy once the reaction has fully resolved and their team judges it safe to restart. For certain severe reactions — particularly ones affecting the heart or nervous system — guidance generally favours permanently stopping the immunotherapy that caused the reaction rather than restarting it.

This decision is always individualised by your treating oncologist, weighing the reaction's severity against how much benefit the immunotherapy was providing against your cancer — never a fixed rule that applies the same way to every patient.

Many second-line treatments begin to show effect within days, though the exact timeline depends on which treatment is used and how severe the reaction was before it started. Your team monitors your symptoms and relevant blood tests closely during this period and may adjust the plan if the response is slower than expected. This step is managed as an inpatient stay or a closely supervised outpatient process, not something you time or judge at home.

Never decide on your own to stop or reduce the steroid course you're already on while a second-line treatment is being started, or to skip a follow-up appointment because symptoms feel better — the two treatments generally continue together until your specialist confirms the reaction has resolved.

Restarting is possible for some patients but is never automatic. Your oncology team weighs how well the reaction resolved, how severe it was, how much benefit the immunotherapy was providing against your cancer, and whether switching to a different treatment approach is safer than restarting the same one. Reactions affecting the heart or nervous system are generally treated as a reason not to restart the same immunotherapy, in line with current oncology guidance.

This is a case-by-case specialist decision, made only once the reaction has fully settled and any second-line treatment has been completed — never a decision to make or push for on your own timeline.

No. For a reaction that isn't responding adequately, staying on steroids alone for longer is not a safer default — it delays effective control of the reaction and extends your exposure to steroid side effects without addressing why the reaction hasn't settled. Never decide on your own to continue steroids longer, raise the dose, or skip a recommended second-line treatment; this decision belongs to your oncology team, based on how you're responding so far, not on how you feel about starting an additional medicine.

Our companion page, Why Steroids Are Used to Treat Immunotherapy Side Effects, covers how the first-line steroid course itself is managed and monitored.

These companion pages go deeper into specific parts of steroid treatment and immune-reaction management — worth reading alongside this one, especially if you're currently on a steroid course.

• Why Steroids Are Used to Treat Immunotherapy Side Effects — how first-line steroid treatment works and what to expect from it.
• Do Steroids Reduce the Effectiveness of Immunotherapy? — the evidence behind the fear that steroids undo treatment benefit.
• Bone Health and Stomach Protection During a Steroid Course — protective steps your team may add during a longer steroid course.
• Immunotherapy at CION Cancer Clinics — how we monitor and support patients through immune-related side effects, from the first infusion onward.

Steroid-Refractory Reactions Are Manageable When Escalated Promptly

Patients who report a slow or worsening response to steroids promptly are supported by the same multidisciplinary team throughout treatment.